FDA 483 - Bavarian Nordic Berna GmbH

An FDA inspection of PaxVax Berna GmbH in Thörishaus, Switzerland, an oral vaccine manufacturer, identified two observations related to incomplete validation activities. Specifically, the firm failed to complete shipping validation for a drug product and validation of the drug supply chain security for a packaging line. These issues indicate potential deficiencies in quality control and supply chain management.